ondansetron has been researched along with Cancer of Head in 7 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess, in a prospective, observational study, the safety and efficacy of the addition of the neurokinin-1-receptor antagonist (NK1-RA) aprepitant to concomitant radiochemotherapy, for the prophylaxis of radiation therapy-induced nausea and vomiting." | 9.20 | Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. ( Jahn, F; Jahn, P; Jordan, K; Riesner, A; Sieker, F; Vordermark, D, 2015) |
| "The purpose of this study was to compare the antiemetic efficacy of three 5-HT3 antagonists (granisetron, ondansetron, tropisetron) plus dexamethasone for the prevention of acute emesis induced by high-dose cisplatin chemotherapy." | 9.09 | Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study. ( Chan, R; Chua, DT; Foo, YC; Kwok, CC; Kwong, DL; Sham, JS; Yue, A, 2000) |
| "A single-institution, prospective, randomized, open controlled trial was carried out on head and neck cancer patients to compare granisetron (GRA), ondansetron (OND), and tropisetron (TRO) in the prevention of cisplatin-induced acute nausea and vomiting." | 9.08 | Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. ( Bianchi, A; Curreli, L; Ghiani, M; Macciò, A; Mantovani, G; Proto, E; Santona, MC, 1996) |
| "To determine a dose-response relationship of ondansetron for the prevention of emesis induced by high-dose cisplatin and to study the efficacy of the extended dosing schedule of ondansetron during 20 hours after cisplatin administration, 36 patients with malignant neoplasms who had not previously received chemotherapy but who were currently receiving cisplatin were treated." | 9.06 | Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. ( Bernard, S; Finn, A; Gandara, D; Khojasteh, A; Lester, E; Sartiano, G; Tapazoglou, E, 1990) |
| "To assess, in a prospective, observational study, the safety and efficacy of the addition of the neurokinin-1-receptor antagonist (NK1-RA) aprepitant to concomitant radiochemotherapy, for the prophylaxis of radiation therapy-induced nausea and vomiting." | 5.20 | Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. ( Jahn, F; Jahn, P; Jordan, K; Riesner, A; Sieker, F; Vordermark, D, 2015) |
| "Palonosetron and ondansetron are two selective 5-hydroxytryptamine (5-HT3) receptor antagonists that have shown remarkable efficacy in controlling nausea and vomiting following administration of moderately emetic anticancer chemotherapy." | 5.14 | Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. ( Atri, R; Bhutani, G; Dhankar, R; Gupta, MC; Kaushal, J; Kaushal, V; Verma, S, 2010) |
| "The purpose of this study was to compare the antiemetic efficacy of three 5-HT3 antagonists (granisetron, ondansetron, tropisetron) plus dexamethasone for the prevention of acute emesis induced by high-dose cisplatin chemotherapy." | 5.09 | Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study. ( Chan, R; Chua, DT; Foo, YC; Kwok, CC; Kwong, DL; Sham, JS; Yue, A, 2000) |
| "A single-institution, prospective, randomized, open controlled trial was carried out on head and neck cancer patients to compare granisetron (GRA), ondansetron (OND), and tropisetron (TRO) in the prevention of cisplatin-induced acute nausea and vomiting." | 5.08 | Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. ( Bianchi, A; Curreli, L; Ghiani, M; Macciò, A; Mantovani, G; Proto, E; Santona, MC, 1996) |
| "Ondansetron, a selective 5-HT3 receptor antagonist, has already been reported to have a marked effect to alleviate or prevent nausea and vomiting associated with cancer chemotherapy, after its intravenous administration." | 5.07 | [Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "To determine a dose-response relationship of ondansetron for the prevention of emesis induced by high-dose cisplatin and to study the efficacy of the extended dosing schedule of ondansetron during 20 hours after cisplatin administration, 36 patients with malignant neoplasms who had not previously received chemotherapy but who were currently receiving cisplatin were treated." | 5.06 | Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. ( Bernard, S; Finn, A; Gandara, D; Khojasteh, A; Lester, E; Sartiano, G; Tapazoglou, E, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jahn, F | 1 |
| Riesner, A | 1 |
| Jahn, P | 1 |
| Sieker, F | 1 |
| Vordermark, D | 1 |
| Jordan, K | 1 |
| Kaushal, J | 1 |
| Gupta, MC | 1 |
| Kaushal, V | 1 |
| Bhutani, G | 1 |
| Dhankar, R | 1 |
| Atri, R | 1 |
| Verma, S | 1 |
| Mantovani, G | 1 |
| Macciò, A | 1 |
| Bianchi, A | 1 |
| Curreli, L | 1 |
| Ghiani, M | 1 |
| Proto, E | 1 |
| Santona, MC | 1 |
| Domínguez-Ortega, L | 1 |
| Cubedo-Cervera, R | 1 |
| Cortés-Funés, H | 1 |
| Díaz-Gállego, E | 1 |
| Chua, DT | 1 |
| Sham, JS | 1 |
| Kwong, DL | 1 |
| Kwok, CC | 1 |
| Yue, A | 1 |
| Foo, YC | 1 |
| Chan, R | 1 |
| Ariyoshi, Y | 1 |
| Ota, K | 1 |
| Taguchi, T | 1 |
| Furue, H | 1 |
| Niitani, H | 1 |
| Tsukagoshi, S | 1 |
| Ikeda, M | 1 |
| Akasaka, Y | 1 |
| Ohta, J | 1 |
| Suminaga, M | 1 |
| Khojasteh, A | 1 |
| Sartiano, G | 1 |
| Tapazoglou, E | 1 |
| Lester, E | 1 |
| Gandara, D | 1 |
| Bernard, S | 1 |
| Finn, A | 1 |
7 trials available for ondansetron and Cancer of Head
| Article | Year |
|---|---|
Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Chemoradiotherapy; Cisplatin; Dexamethasone; Drug Th | 2015 |
Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
Topics: Acute Disease; Adult; Antiemetics; Antineoplastic Agents; Cross-Over Studies; Dexamethasone; Drug Th | 2010 |
Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Female; Gr | 1996 |
Sleep protects against chemotherapy induced emesis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Dexamethasone; | 1996 |
Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Dexamethasone; Femal | 2000 |
[Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].
Topics: Administration, Oral; Adult; Aged; Cisplatin; Double-Blind Method; Female; Head and Neck Neoplasms; | 1992 |
Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dose-Response Relationship, Drug; Drug Admin | 1990 |